Filing identity and reporting period
The supplied document is OXIS International, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, filed January 8, 2015. It is not identified as a GT Biopharma, Inc. filing; verify the issuer before relying on this summary.
OXIS focused on products related to oxidative stress, especially ergothioneine (ERGO/EGT), including nutraceutical and skin-care products, and potential licensing of proprietary compounds. It reported limited operations and revenue. The filing also describes a planned cannabinoid therapeutics business through subsidiary Oxis Biotech, formed in September 2014.
Financial performance and position
| Metric | 2013 | 2012 |
|---|---|---|
| Revenue | $368,000 | $342,000 |
| Cost of product revenue | $226,000 | $94,000 |
| Gross profit and margin | $142,000; 38.6% | $248,000; 72.5% |
| Operating expenses | $935,000 | $3,762,000 |
| Operating loss | $(793,000) | $(3,514,000) |
| Net loss | $(501,000) | $(5,171,000) |
| Net cash used in operating activities | $(442,000) | $(987,000) |
| Cash and cash equivalents at year-end | $43,000 | $123,000 |
| Total assets | $147,000 | $226,000 |
| Total liabilities | $6,481,000 | $6,562,000 |
At year-end 2013, current assets were $125,000, current liabilities were $6,384,000, and the working-capital deficit was $6,259,000. Accumulated deficit was $89,467,000. Interest expense was $1,196,000, versus $1,653,000 in 2012. The filing does not provide a clear standalone EBITDA or operating-margin measure.
Material changes versus 2012
- Revenue rose 7.6%, but cost of product revenue increased substantially, reducing gross profit by $106,000 and gross margin from approximately 72.5% to 38.6%.
- Selling, general and administrative expense fell by $2,427,000, primarily due to lower stock-based compensation, advertising and consulting costs. Research and development expense was zero in both years.
- Net loss improved by $4,670,000. A $1,425,000 gain from changes in the fair value of warrant and derivative liabilities, compared with a $94,000 expense in 2012, materially affected the comparison; this was not operating revenue.
- Operating cash use declined, but cash fell by $80,000 during 2013. Financing activities provided $425,000 net, chiefly through notes payable.
- Common shares outstanding increased from approximately 500.6 million to 573.1 million. At year-end, the company also had approximately 591.0 million warrants outstanding.
Outlook, risks and unusual items
- Going concern: The auditor and management cited substantial doubt about OXIS’s ability to continue as a going concern, given recurring losses, minimal cash and dependence on additional financing. The statements contain no adjustments for a possible inability to continue operations.
- Funding and liquidity: Management said year-end cash would cover administrative expenses for the next 12 months, but also said expenses could approach $5 million annually if the Oxis Biotech strategy advanced and that it would seek $5 million in funding in Q1 2015. Neither financing nor business-plan execution was assured.
- Debt and dilution: The company relied on convertible debentures and demand notes, including 2013 instruments with 10% interest and conversion prices as low as $0.007 per share, alongside warrants. These financing terms create potential dilution. Certain legacy debt was secured by substantially all assets; the filing describes defaults and unpaid obligations on older debentures.
- Controls and governance: Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2013 and identified material weaknesses, including inadequate segregation of duties and risk of executive override. A new CFO was hired in November 2014. None of the three directors was considered independent, and the board performed committee functions as a whole.
- Commercial and regulatory execution: Product plans depended on outsourced manufacturing, marketing and distribution. Consumer health claims and products are subject to FDA, FTC and other regulation; the filing notes that claims may be restricted and compliance can add cost. OXIS had two employees as of December 2014.
- Business development and legal matter: The ERGO skin-care business had limited sales, and planned products and cannabinoid drug candidates remained development-stage initiatives. A 2014 licensing dispute was resolved for a cash payment and perpetual royalty on future product sales; amounts were not stated in the supplied text.
- The filing states that it qualifies as a smaller reporting company and therefore omits the Item 1A risk-factor disclosure.
Key facts for investors to verify
- Confirm the issuer: the filing and financial statements are for OXIS International, Inc., notwithstanding the request metadata naming GT Biopharma, Inc.
- Review the audited statements and notes for current debt balances, defaults, collateral rights, conversion terms, and subsequent financings; the filing reports only $43,000 of cash against a $6.259 million working-capital deficit at year-end.
- Assess the scale of potential dilution from convertible securities, warrants, options and later share issuances, and reconcile those instruments with the reported share counts.
- Check whether the proposed $5 million financing and Oxis Biotech plans were completed, and whether subsequent operations generated revenue or required additional capital.
- Evaluate remediation of the disclosed material weaknesses and whether later filings report improved controls, independent governance and adequate financial reporting.